Epigenomics AG (EPGNF) Research

Epigenomics AG, established in 1998 and headquartered in Berlin, Germany, is a molecular diagnostics firm dedicated to the early identification of cancer through liquid biopsy technologies. The company's flagship product, Epi proColon, is a blood-based screening test for the early detection of colorectal cancer, distributed across the United States, Europe, and China. Its product portfolio also encompasses a blood test for hepatocellular carcinoma and Epi BiSKit, a pre-analytical kit that supplies reagents essential for preparing bisulfite-converted DNA. Epigenomics' research and development initiatives concentrate on pinpointing appropriate biomarkers in human tissue and subsequently developing and patenting corresponding in vitro diagnostic blood tests.

Market snapshot

Symbol
EPGNF
Price
$1.12
Day change
0.00%
Market cap
$612.6K
P/E ratio
-0.24x
52-week range
0.79-1.12
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Body and Mind Inc. (BMMJ)
  • China Medicine Corporation (CHME)
  • Health Logic Interactive Inc. (CHYPF)
  • Next Generation Management Corp. (NGMC)
  • NovelStem International Corp. (NSTM)
  • Procyon Corporation (PCYN)
  • PPJ Healthcare Enterprises, Inc. (PPJE)
  • RushNet, Inc. (RSHN)

Open Epigenomics AG (EPGNF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.